Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · NEULANDLAB

NEULAND LAB.

HealthcarePharmaceuticals & Biotechnology₹27570 cr market cap
₹21105.00 ▼ -1.63% today As of 19 Nov 2026
52-week low ₹11555.0052-week high ₹23995.00

-10.6% from the 52-week high · +85.7% above the low

Neuland Laboratories Ltd. engages in the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company is headquartered in Hyderabad, Telangana and currently employs 1,521 full-time employees. The firm is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The firm operates through manufacture of active pharmaceutical ingredients and allied services. The firm has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services. The Company’s capabilities include FBRM, research and development, peptide laboratory, poly block reactors, laboratory reactors, heating and cooling systems, hazardous and wet laboratory, PID Laboratory Unit-III, PID Laboratory B-S Unit-I, and other lab equipment. The firm has 3 manufacturing facilities and one R&D facility in Hyderabad.

The short version. NEULAND LAB. reported revenue of ₹450 crore for Sep 2026, down 12.5% from a year earlier. Net profit was ₹52 crore (down 46.4% year on year). Return on equity was 19.4% in Mar 2026. Promoter holding was 32.26% in Sep 2026, down 0.42 points over 8 quarters.

1 · The price

How has the stock traded?

NEULAND LAB. trades 10.6% below its 52-week high and 85.7% above its 52-week low.

Change over period: —

1M+11.6%
3M-7.9%
6M+29.1%
1Y+24.4%

2 · The business

Is it growing?

Sales, year on year-12.5%

Sep 2026 revenue of ₹450 cr.

Profit, year on year-46.4%

Sep 2026 net profit of ₹52 cr.

Net margin11.5%

7.3 pts lower than a year earlier.

3-year growth30.6% profit

Revenue compounded at 19.6% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue450642776440514293328398
Net profit5214821341971428102
Net margin %11.523.027.49.218.84.78.525.5
EPS (₹)40.24115.1165.7631.6275.4910.8321.6779.18

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue2023147715591191951937763667
Net profit36426030016464811616
Net margin %18.017.619.313.76.78.62.12.5
EPS (₹)283.71202.74233.89127.4549.7462.8512.6312.82

3 · The quality

How well does it turn capital into profit?

Return on equity was 19.4% in Mar 2026; debt to equity is 0.10.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %19.417.123.416.4
Return on capital %23.120.729.620.1
EBITDA margin %29.428.130.223.4
Net margin %17.717.419.113.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR19.6%16.6%
Profit CAGR30.6%35.2%
Debt to equity0.10
Interest cover21.4x
Current ratio2.09
P/E ratio61.3

4 · The owners

Who holds it, and are they adding?

Promoter holding32.26%

Down 0.42 pts over 8 quarters.

Foreign institutions21.93%

Down 1.93 pts over 8 quarters.

Domestic institutions16.26%

Up 7.18 pts over 8 quarters.

Mutual fund schemes128

+43 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter32.6832.6732.6732.6432.6332.6332.6232.26-0.42
FII23.8622.1121.6920.620.920.4621.0821.93-1.93
DII9.0810.9711.5713.5414.7115.8416.5116.26+7.18
Public33.9833.8433.6732.8131.7631.0729.7929.55-4.43

Mutual fund holdings · Oct 2026

128 schemes hold this stock

85 the month before.

  • LIC MF HEALTHCARE FUND5.83% of NAV
  • Bajaj Finserv Healthcare Fund3.41% of NAV
  • LIC MF SMALL CAP FUND3.28% of NAV
  • LIC MF FLEXI CAP FUND3.21% of NAV
  • LIC MF MID CAP FUND3.15% of NAV
  • HDFC Pharma and Healthcare Fund2.96% of NAV
  • HDFC MNC Fund2.88% of NAV
  • SAMCO ELSS TAX SAVER FUND2.85% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for NEULAND LAB. are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about NEULAND LAB.

What is the NEULAND LAB. share price?

NEULAND LAB. (NEULANDLAB) last closed at ₹21,105.00, down 1.63% on the day. Its 52-week range is ₹11,555.00 to ₹23,995.00.

What is the market cap of NEULAND LAB.?

NEULAND LAB. has a market capitalisation of about ₹27,570 crore. Its price-to-earnings ratio is 61.3.

How are NEULAND LAB.'s latest results?

NEULAND LAB. reported revenue of ₹450 crore for Sep 2026, down 12.5% from a year earlier. Net profit was ₹52 crore (down 46.4% year on year). Return on equity was 19.4% in Mar 2026. Promoter holding was 32.26% in Sep 2026, down 0.42 points over 8 quarters.

Who owns NEULAND LAB.?

As of Sep 2026, shareholding was: Promoter 32.26%, FII 21.93%, DII 16.26%, Public 29.55%.

How many mutual funds hold NEULAND LAB.?

128 mutual fund schemes held NEULAND LAB. in October 2026. That compares with 85 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 18 Jul 2025 · Final Dividend - Rs. 12
  • 12 Jul 2024 · Final Dividend - Rs. 14
  • 11 Jul 2023 · Final Dividend - Rs. 10
  • 14 Jul 2022 · Final Dividend - Rs. 5
  • 29 Jun 2021 · Final Dividend - Rs. 3
  • 10 Nov 2020 · Interim Dividend - Rs. 2

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.